Table 3 Concentrations of anti-Hsp60 and anti-Hsp65 IgG antibodies in group of women with ovarian cancer depending on stage of clinical disease progression (by FIGO) and in control group
From: Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer
| Â | Stage of clinical disease progression (by FIGO) | Controls | |||
|---|---|---|---|---|---|
I | II | III | IV | n = 80 | |
n = 25 | n = 31 | n = 60 | n = 33 | ||
Anti-Hsp60 (AU/ml) | 126,99a)b)e) | 97,15c)e) | 91,92 | 70,87 | 62,42 |
(mean ± SD) | ± 121,90 | ± 91,82 | ± 160,11 | ± 78,70 | ± 33,92 |
  % of positive results | 46%f) | 27%f) | 17% | 17% | 10% |
  (> 90 percentile for control group) | p = 0.0000 | p = 0.0213 | p = 0.2047 | p = 0.2861 | |
Anti-Hsp65 (AU/ml) | 190,34a)b)e) | 97,80c)e) | 89,36d) | 44,17 | 56,35 |
(mean ± SD) | ± 337,27 | ± 90,59 | ± 137,58 | ± 26,07 | ± 35,58 |
  % of positive results | 46%f) | 27%f) | 21% | 0%f) | 10% |
  (> 90 percentile for control group) | p = 0.0000 | p = 0.0213 | p = 0.0594 | p = 0.0493 | |